A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Colorectal Cancer|Ovarian Cancer|Non-Small Cell Lung Cancer|Acral Lentiginous Melanoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|Esophageal Squamous Cell Carcinoma|Urothelial Carcinoma|DMMR Colorectal Cancer|MSI-H Colorectal Cancer|Melanoma|Platinum-Resistant Primary Peritoneal Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Epithelial Ovarian Cancer|Triple Negative Breast Cancer
Interventions: BIOLOGICAL: ATRC-101|BIOLOGICAL: Pembrolizumab|DRUG: Pegylated liposomal doxorubicin (PLD)
Sponsor: Atreca, Inc.